停牌核查完成合富中国今日复牌

Group 1 - The company announced the completion of a stock suspension review, with shares resuming trading on November 20, 2025 [2] - During the period from October 28 to November 14, 2025, the company's stock experienced a significant increase, closing at the daily limit on 12 out of 14 trading days, with a cumulative rise of 256.29% [2] - The company reported that its current stock price significantly deviates from its operating performance and industry conditions, leading to a temporary suspension of trading [2] Group 2 - The company's current price-to-earnings (P/E) ratio is 343.67, which is substantially higher than the industry average P/E ratio of 30.94, indicating a potential bubble in the stock price [3] - The company is currently operating at a loss, with a net profit of -5.048 million yuan for Q3 2025, a year-on-year decline of 225.26%, primarily due to changes in the domestic macroeconomic environment and price reductions in the medical industry [3] - Despite implementing cost control measures, the company faces pressure on its short-term operating performance due to a decline in sales revenue and profit levels [3]